Tevogen Bio Holdings Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $44.0M
- Price
- $6.75
- % Change (Daily % change from the live per-ticker quote feed.)
- +5.97%
- Volume
- 13.0K
About
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Quick stats
Shares outstanding4.2M
Computed float9.9M
Float / shares235.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001860871
Websitehttps://tevogen.com
AI Summary
AI-generated1/14
minorneutralticker change
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
Tevogen Bio Holdings Inc. will operate under the name Tevogen Inc. effective July 30, 2026, following approval by its Board of Directors.
The rebranding reflects the company's evolution into a broader healthcare enterprise integrating biotechnology, artificial intelligence, and healthcare services.
Trading on Nasdaq will continue under the existing ticker symbols TVGN and TVGNW with no changes to CUSIP numbers.